Integrated Omics and Systems Pharmacology-Based Drug Discovery for COVID-19: An Overview
Kruthi Ashok Kumar, Rithika Shibu, Raunak Kumar Das, Ramya Shanmugam, Alagarsamy Sumitrha, Shanmugam Gavaskar, Shanmugam Velayuthaprabhu, Arumugam Vijaya Anand · Apple Academic Press eBooks · 2025
Omics comprises various fields of biology, including transcriptomics, phenomics, proteomics, genomics, etc. These fields are characterized by the analysis of a cell’s entire biological process or by the characterization of a biomolecule’s complexity. With the rapid advancements in high-throughput (HTP) omics technologies, approaches to analyzing biological samples can generate tera- to peta-byte-sized data files. These advancements have started to enable personalized medicine at a comprehensive molecular level. The integration of multi-omics has evolved a more detailed view of diseases. COVID-19, the dreadful disease of the time, has been the top priority in finding a preventive cure against it. Despite the thriving development of SARS-CoV-2 vaccines, efficacious and validated therapeutic compounds for therapy have not yet been identified. The virus’s metagenome, proteome, 58 and genome sequence investigations have contributed to our understanding of its nature and mode of disease propagation. Numerous instruments and techniques are available in multi-omics approaches to help find possible COVID-19 medicinal biomolecules. Systems pharmacology has emerged to focus on the action of drugs at the organ level, integrating traditional pharmacodynamic modeling and pharmacokinetics with recent systems biology approaches. This chapter focuses on the complementary effects of multi-omics integration along with systems pharmacology for COVID-19.